A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Thi pahse I, dose-escalation trial will determine the MTD, safety and the additional benefit
achieved from adding SGI-110 to ipilimumab therapy in metastatic melanoma patients.
Preclinical evidence generated with SGI-110 in vivo demonstrated that besides having a direct
activity on tumor growth as a single agent, SGI-110 was able to "sensitize" neoplastic cells
to the anti-tumor activity of CTLA-4 blockade, providing a sound scientific rationale to
develop new immunotherapeutic approaches combining SGI-110 with therapeutic mAb to immune
check-points.